Skip to main navigation

Header Nav

Company
Pipeline and Technology
Business Development
Investors
Contact Us

Select Page

Press Releases

Header Nav

Welcome
Financial Information
Financial Fundamentals
Stock Information
- Stock Quote & Chart
- Historic Price Lookup
Filings
- SEC Filings
- Ownership
Corporate Governance
Corporate Presentation
Events
Press Releases
Investor Alerts

Toolkit

Email Alerts
Print Page
Share
RSS Feeds
Contact IR
Search

Press Releases

Year

Apr 20, 2022

Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic Shock

Istaroxime significantly improved the systolic blood pressure profile WARRINGTON, Pa. , April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders,

Mar 31, 2022

Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference

Company to present on Monday, April 4, 2022 at 11:00 am WARRINGTON, Pa. , March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that

Mar 31, 2022

Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates

WARRINGTON, Pa. , March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended

Mar 22, 2022

Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury

Results support the feasibility for development of a potential treatment for critically ill patients with ARDS due to COVID-19 and other causes WARRINGTON, Pa. , March 22, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple

Mar 15, 2022

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

On track for top-line data in April 2022 WARRINGTON, Pa. , March 15, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has

Mar 10, 2022

Windtree to Present at Oppenheimer’s 32nd Annual Healthcare Conference

WARRINGTON, Pa. , March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser , President and

Feb 1, 2022

Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome

Data anticipated in first quarter 2022 WARRINGTON, Pa. , Feb. 01, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has completed

Pagination

First page
Previous page
Page 1
Current page 2

YM Twitter Feed